Procept BioRobotics Faces Class Action Over Revenue Allegations

The litigation, filed in the U.S. District Court for the Northern District of California, targets the company’s financial disclosures between February 28, 2024, and February 25, 2026. Plaintiffs allege that Procept incentivized bulk handpiece orders that far exceeded actual clinical demand, creating a significant surplus of field inventory. According to the complaint, these practices obscured the reality that handpiece sales consistently outpaced actual procedures by 8% to 16% per quarter.

For pension funds and asset managers, the sharp valuation drop warrants a granular review of transaction records during the period in question. Law firm Levi & Korsinsky, which is representing the shareholders, emphasizes that institutional fiduciaries must now determine if their holdings were purchased at prices artificially bolstered by these recurring revenue assumptions. The case aims to address whether executives misled the market regarding the sustainability of the company's growth metrics.